Skip to content
Review Open access

Topical Nasal Furosemide for the Prevention of Postoperative Nasal Polyp Recurrence: A Systematic Review

Oct 2026 · RCMOS - Revista Científica Multidisciplinar O Saber · 0 citations · 5 references

Abstract

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is defined by high postoperative recurrence rates. While standard therapies target inflammation, the crucial role of mucosal edema secondary to epithelial ion transport dysregulation offers a new therapeutic target. This systematic review aims to critically evaluate the evidence for the efficacy and safety of topical nasal furosemide, a Na-K-2Cl cotransporter (NKCC1) inhibitor, in preventing polyp recurrence following endoscopic sinus surgery (ESS). Methods: A comprehensive search of PubMed (MEDLINE), Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted through September 2026. We included all randomized controlled trials (RCTs) comparing topical nasal furosemide to a placebo control in adults who had undergone ESS for CRSwNP. Results: The search identified two high-quality, double-blind RCTs meeting the inclusion criteria (n=143). Both studies demonstrated a significant benefit for topical furosemide. One trial reported a nearly three-fold reduction in the polyp recurrence rate at 3 months (16.6% for furosemide vs. 43.3% for placebo; p < 0.05). The second, a multicenter trial, found a statistically significant and clinically relevant improvement in the Lund-Kennedy endoscopic score at 12 weeks (mean change of -1.13 for furosemide vs. -0.28 for placebo; p = 0.02). Across both studies, topical furosemide was exceptionally well-tolerated, with a safety profile comparable to placebo and no reported systemic adverse events. Conclusion: The current evidence, though limited to two key trials, consistently supports topical nasal furosemide as an effective and safe postoperative strategy for mitigating polyp recurrence. By directly targeting mucosal edema, it represents a novel mechanistic approach that complements traditional anti-inflammatory therapies. These promising findings warrant larger, long-term clinical trials to definitively establish its role in the clinical management of CRSwNP.  

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.